OTLK

Insider trade Purchase by Sukhtian Ghiath M.

10h ago

Insider trade Purchase by GMS Ventures & Investments

10h ago

SEC filing OTLK Resubmits Biologics License Application for ONS-5010/LYTENAVA™, Expects PDUFA Decision Within 60 Days

1d ago

Scanner Large up move: 46.3% (2.9x normal daily movement)

4d ago

Scanner Large up move: 46.3% (3.0x normal daily movement)

4d ago

Insider trade Purchase by Sukhtian Faisal Ghiath

5d ago

Insider trade Purchase by Haddadin Yezan Munther

5d ago

Insider trade Purchase by THURMAN RANDY H

5d ago

Insider trade Purchase by HILZINGER KURT J

5d ago

SEC filing OTLK Wins FDA Appeal, Plans BLA Resubmission in June 2026 for ONS-5010/LYTENAVA™ with Anticipated Class 1 Resubmission and PDUFA Date within 60 Days

7d ago

Short volume Short volume 67% of volume (3.4σ)

18d ago

SEC filing OTLK Priced $5M Offering 16.1M Shares $0.31 Each 16.1M Warrants Exercise $0.31 5Yr Expiry Stockholder Vote Needed 4.99% Cap Placement Agent 7% Fee

39d ago

SEC filing OTLK Completes FDA FDR Meeting for ONS-5010/LYTENAVA, Formal Decision Expected May 2026

41d ago

SEC filing OTLK Prices $5M Offering 20M Shares $0.25 Each + Warrants, Net $4M Proceeds, 7% Placement Agent Fee, $100K Counsel Fees, 1.4M Agent Warrants $0.3125 Exercise Price, Expires 2031

68d ago

News Outlook Therapeutics stock slides after pricing $5M offering

70d ago

News Outlook Therapeutics Announces Proposed Public Offering

70d ago

News Outlook Therapeutics launches public offering; shares down

70d ago

SEC filing OTLK Reports $8.7M Cash, $33.1M March 2025 Note, $18.36M March 2026 Note, $10.8M Remaining Debt, Substantial Doubt

78d ago

SEC filing OTLK Reports $0 Revenue, $0 EPS, Updates FDA Meeting on ONS-5010/LYTENAVA™ CRL, Phase 3 NORSE TWO Meets Endpoints, Seeks Approval Pathways

88d ago

SEC filing OTLK Reports $23.1M Net Loss, $0.38 EPS, LYTENAVA™ Sales Double QoQ in Europe, Seeks FDA Guidance on ONS-5010

105d ago

News Live Ventures outlines AI-driven operational strategy while reporting $7.8M adjusted EBITDA growth

109d ago

News Natural Health Trends outlines $1.5M cost savings for 2026 as restructuring nears completion

117d ago

News Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus

150d ago

SEC filing OTLK Reports $1.4M Revenue, $62.4M Net Loss, Launches LYTENAVA in Europe, Awaits FDA Decision

165d ago

Scanner Unusual volume (z=3.6)

165d ago